Gary Kirsh, MD, president of The Urology Group and the Large Urology Group Practice Association (LUGPA), discusses the future of treatment for prostate cancer.

Localized prostate cancer continues to be treated using robotic surgery and radiation therapy, but advancements have recently been made in treatment for advanced prostate cancer.

Several agents have been approved since 2010 for advanced prostate cancer, including immunotherapy, targeting agents, and hormonal therapy. Additional agents are also anticipated to be approved soon, Kirsh adds.

In the future, Kirsh says that he sees urologists being increasingly involved in advanced prostate cancer. Urologists in LUGPA have the wherewithal and infrastructure to put together pathways and algorithms for prostate cancer treatments, Kirsh says.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Prostate Cancer

JAN-22-OSD1189 - /clinical/prostate-cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Kirsh Discusses the Future of Treating Prostate Cancer